STAT+: Janet Woodcock revolutionized the way the FDA reviews cancer drugs, inspiring her supporters and raising concerns for detractors

WASHINGTON — In 2000, the Food and Drug Administration approved just three cancer drugs. Last year, even with the agency laser-focused on the coronavirus pandemic, much of its staff teleworking, the agency still approved a record-breaking 17 different cancer therapies — more than in any other category.

That’s the legacy of FDA drug center chief Janet Woodcock.

Continue to STAT+ to read the full story…

STAT+: Janet Woodcock revolutionized the way the FDA reviews cancer drugs, inspiring her supporters and raising concerns for detractors

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top